We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Deep Brain Stimulation Successfully Treats Severely Depressive Patient

By HospiMedica International staff writers
Posted on 22 Jan 2010
A 64-year-old woman, who had suffered from depression since age 18, was successfully treated by using deep-brain stimulation (DBS) to excite the habenula, a tiny nerve structure in the brain. More...


A team of neurosurgeons at Heidelberg University Hospital (Germany) and psychiatrists at the Central Institute of Mental Health (Mannheim, Germany) performed DBS by inserting electrodes into the habenulae, which were then connected with wires under the skin to an electronic impulse generator implanted in the chest. The electrodes emit current that continuously stimulate the nerve structure. The procedure was complex, as the target area is about half as large as other sites that are typically targeted for movement disorders, and in addition, is located in the middle of the brain, in the wall of what is known as the "third ventricle.” The success of the procedure was confirmed when the electrode was accidentally switched off; the patient had a bicycle accident which required surgery for which an ECG had to be made as preparation. The brain pacemaker was switched off and was not reactivated for a few days, and the depression promptly returned. A few weeks after reactivation, the patient completely recovered again. The concept of habenula stimulation and the case study were published in January 15, 2010, issue of the journal Biological Psychiatry.

"We decided to stimulate the habenula because it is involved is the control of three major neurotransmitter systems, which are known to be disturbed in depression,” said lead author psychiatrist Alexander Sartorius, M.D., of the Central Institute of Mental Health. "We aim to show that habenula stimulation has a better success rate than other target areas attempted for depression and that it is also safe to use.”

The neurosurgeons in Heidelberg and the psychiatrists in Mannheim now want to build on this positive experience and are planning a clinical study in which the habenula stimulation is to be implemented for severely depressive patients at five psychiatric-neurosurgery centers in Germany.

The habenula refers to a neighboring group of nerve cells with which the pineal gland was believed to be associated, the habenular nucleus. Currently, the term refers exclusively to this separate cell mass in the caudal and dorsal aspect of the dorsal thalamus (the epithalamus), embedded in the posterior end of the medullary stria from which it receives most of its afferent fibers.

Related Links:
Heidelberg University Hospital
Central Institute of Mental Health



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
IV Therapy Cart
Avalo I.V Therapy Cart
Half Apron
Demi
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.